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Abstract
Mutations in the Neurofibromatosis 2 gene (NF2) predispose to tumors of the nervous system, mainly schwannomas
and meningiomas. TheNF2 gene encodes for the tumor suppressor protein merlin (moesin-ezrin-radixin–like protein),
which functions as a linker between the plasma membrane and the cytoskeleton. Carboxyterminal phosphorylation
affectsmerlin activity, but many open questions on the regulation ofmerlin function still remain. The phosphoinositide
3-kinase/Akt pathway is activated in human vestibular schwannoma, suggesting a role for Akt-dependent merlin
regulation in the formation of these tumors. In this study, we identify merlin serine 10 as a novel substrate for Akt
phosphorylation. We demonstrate that this N-terminal phosphorylation directs merlin for proteasome-mediated
degradation and affects merlin binding to the E3 ligase component DCAF1. Our data indicate that sequential phos-
phorylation of merlin C- and N-terminus by different oncogenic kinases targets merlin for degradation and thus
downregulates its activity. On the basis of these findings, we propose a model for a posttranslational mechanism
of merlin inactivation.
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Introduction
The NF2 tumor suppressor merlin, encoded by the NF2 gene, regu-
lates proliferation in many cell types [1]. Merlin belongs to the ERM
(ezrin-radixin-moesin) family of proteins that all function as linkers
between the cell membrane and cytoskeleton [2]. Like the other
ERM proteins, merlin can also form intramolecular N- to C-terminal
associations known to affect its activity [3–5]. The function of merlin is
regulated through phosphorylation of a C-terminal serine 518 (S518),
which is a substrate for both p21-activated kinase (PAK) and protein
kinase A (PKA) [6–9]. Phosphorylation of S518 is predicted to unfold
merlin and lead to reduced inhibition of cell growth, whereas dephos-
phorylation of S518 by the moesin phosphatase MYPT-1-PP1δ acti-
vates the tumor suppressor function of merlin leading to growth arrest
[10,11]. However, the exact mechanism by which S518 phosphoryla-
tion regulates merlin’s tumor-suppressive activity is still open. In addition
to the C-terminal serine, merlin is phosphorylated by PKA on serine 10
(S10), which leads to modulation of the actin cytoskeleton [12].
The serine/threonine kinase Akt (protein kinase B) regulates many
cellular processes such as motility, growth, and apoptosis. The phospho-
inositide 3-kinase (PI3K)/Akt signaling pathway is growth-promoting
in many human malignancies, and overexpression or hyperactivation
of Akt is often associated with tumor development [13]. Three genes
encode for the mammalian Akt isoforms: PKBα (Akt1), PKBβ (Akt2),
and PKBγ (Akt3). Akt1 is ubiquitously expressed at high levels; Akt2
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is highly expressed in insulin-sensitive tissues such as liver, skeletal mus-
cle, and adipose tissue; whereas the highest expression of Akt3 is seen in
the brain and testis [14]. The Akts are regulated by phosphoinositide-
dependent kinase 1 (PDK1), which acts downstream of PI3K and phos-
phorylates Akt on threonine 308 in its activation loop [15], but full
activation of Akt requires additional phosphorylation on serine 473 [16].
Activation of the PI3K/Akt pathway has been implicated in survival
of Schwann cells [17] that are susceptible to tumor formation in the
NF2 disease, and several studies indicate an interplay between merlin
and Akt. Merlin plays a role in controlling the PI3K/Akt pathway by
inhibiting Akt signaling [18,19], and the pathway is activated in both
human schwannoma [20–22] and in malignant mesotheliomas from
Nf2 +/− mice [23]. Recently, Akt-mediated phosphorylation of merlin
was also described [24], but there are still open questions about the
biologic effects of Akt on merlin.
In this report, we have studied the phosphorylation of merlin and
identified S10 as an Akt phosphorylation site. Our results show that this
N-terminal phosphorylation directs merlin for proteasome-mediated
degradation thereby affecting merlin function. These findings impli-
cate a mechanism, by which the oncogenic Akt pathway can regulate
cell growth.
Materials and Methods
Cells, Plasmids, and Antibodies
COS-7 cells were maintained in Dulbecco minimum essential me-
dium (Gibco-Invitrogen, Carlsbad, CA) with 10% fetal bovine serum
(PromoCell, Heidelberg, Germany) and antibiotics.
For the expression of recombinant GST-merlin fusion proteins,
merlin fragments 1-100, 1-314, 314-477, 1-547, and 492-595 in
pGEX4T1 vector (Amersham Biosciences, Uppsala, Sweden) were used.
Human merlin isoform I (WT, amino acids 1-595) in pcDNA3 vector
(Invitrogen) was used for transfection experiments. The point muta-
tions S10A, S10D, T230A, S315A, S518A, and S518D were made
by site-directed mutagenesis in both vectors using the QuikChange
Kit (Stratagene, La Jolla, CA). The authenticity of all constructs was
verified by sequencing. Akt WT in pUSEamp vector was from Upstate
Biotechnology (Temecula, CA). The cDNAs of bovine myristoylated
Akt and myristoylated kinase-dead Akt were kind gifts from Dr Rene H.
Medema. Both constructs contain N-terminal myristoylation sig-
nals, and the Akt KD construct has a K179A mutation in the catalytic
domain. The DCAF1 in pRK5 vector was obtained from Dr Filippo
Giancotti and had been described [25].
Antimerlin pAb A-19 sc-331 (Santa Cruz Biotechnology, Santa
Cruz, CA) and KF10 monoclonal antibody (mAb) [26] were used to
detect merlin. S518 phosphorylated merlin was detected with pS518
pAb (Biodesign, Saco, ME). Rabbit polyclonal antibody recognizing
human merlin phosphorylated on S10 was produced by immunization
of a 11-mer synthetic phosphopeptide IASRM(pS)FSSLK and sub-
sequent purification of the antiserum using both negative and positive
affinity purification methods. The specificity of the antibody was tested
against in vitro Akt-phosphorylated GST-merlin with and without
S10A mutations. Rabbit monoclonal pan-Akt and phospho-Ser473
Akt antibodies (Cell Signaling Technology, Danvers, MA) were used
for Akt detection, phospho-GSK-3α/β (Ser21/9) (Cell Signaling Tech-
nology) and GSK-3α (Santa Cruz Biotechnology) antibodies were
used for GSK3 detection, and anti-VprBP antibody (SMS-Gruppen,
Rungsted, Denmark) was used for DCAF1 detection. The Ub (P4G7)
antibody (Santa Cruz Biotechnology) was used for monoubiquitin and
polyubiquitin detection. GST fusion proteins were detected with GST
Ab (GEHealthcare, Uppsala, Sweden), and tubulin with α-tubulinmAb
(Sigma-Aldrich, St Louis, MO). Alexa-488– and Alexa-594–conjugated
goat antimouse and goat antirabbit antibodies (Invitrogen-Molecular
Probes) were used as secondary antibodies in immunofluorescence, and
horseradish peroxidase–conjugated rabbit antimouse, swine antirabbit
(DAKO A/S, Glostrup, Denmark), and swine antigoat (Santa Cruz
Biotechnology) secondary antibodies were used in Western blot analysis.
Transfections, Immunofluorescence, and Immunoblot Analysis
Cells were transfected using FuGENE 6 transfection reagent
(Hoffmann-La Roche Ltd, Basel, Switzerland) and incubated for
48 hours before analysis. For Akt kinase activation and inhibition ex-
periments, cells were cultured in serum-free medium for 24 hours
and treated before lysis with 0.2 μg/ml human recombinant EGF
(Calbiochem, La Jolla, CA) for 10 minutes, with 50 μM LY-294002
(Sigma-Aldrich) for 1 hour or with 0.1 μM Calyculin A (Calbiochem)
for 10 minutes all at 37°C. For degradation assays, serum-starved
cells were treated for 24 hours (or 3 hours for ubiquitination experi-
ment) with 5 μM of the proteasomal inhibitor MG132 or 0.1 μM of
Bafilomycin A1 (both from Sigma-Aldrich) used to inhibit lysosomal
function. To activate or inhibit endogenous PKA activity, cells were
treated with 50 mM IBMX and 25 mM forskolin or 10 μM H89
(all from Sigma-Aldrich) for 24 hours. For Western blot analysis of
fractionated lysates, cells were rinsed with phosphate-buffered saline
and lysed in ELB buffer (50 mM HEPES, pH 7.4, 150 mM NaCl,
5 mM EDTA) containing 0.5% Nonidet P-40 (NP-40), HALT phos-
phatase inhibitors (Pierce, Rockford, IL), and complete protease inhib-
itors (Roche). Lysed cells were centrifuged at 13,000g for 20 minutes
at +4°C, and the pellet and supernatant were resolved in equal amounts
of reducing Laemmli buffer. Whole-cell lysates were prepared by add-
ing reducing Laemmli sample buffer on the plates. Samples were re-
solved on SDS-PAGE, transferred to nitrocellulose filters, and analyzed
by immunoblot analysis with appropriate antibodies using enhanced
chemiluminescence detection (Amersham Biosciences). For immuno-
fluorescence, cells grown on glass coverslips were fixed in 3.5% para-
formaldehyde (pH 7.5) and detected with appropriate antibodies using
standard protocols.
Immunoprecipitation
COS-7 cells were lysed 48 hours after transfection in ELB buffer
containing 0.5% NP-40, HALT phosphatase inhibitors, and complete
protease inhibitors. Lysed cells were centrifuged at 13,000g for 30 min-
utes at 4°C. The supernatants were diluted 1:1 to ELB buffer without
NP-40 and precleared with G-sepharose beads for 1 hour at 4°C. Beads
were spun down, and cleared supernatants were incubated with appro-
priate antibodies overnight at 4°C under rotation. G-Sepharose beads
were added and the samples were incubated for additional 4 hours at
4°C under rotation. Immunoprecipitates were washed with ELB buffer,
and bound proteins were eluted from the beads by boiling in non-
reducing Laemmli buffer and analyzed by immunoblot analysis.
In Vitro Phosphorylation of Merlin
GST fusion proteins were expressed in Escherichia coli DH5α
and purified. Glutathione-Sepharose beads (Amersham Biosciences)
to which ∼4 μg of fusion protein was conjugated were washed in Akt
buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 15 mM DTT,
15 mM MgCl2, 100 μM ATP) or PKC buffer (1/5 PKC lipid ac-
tivator [Upstate Biotechnology], 20 mM HEPES, 10 mM MgCl2,
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0.1 mM EGTA, 500 μM ATP) containing complete protease inhibi-
tors. The phosphorylation reaction was carried out in a 30-μl buffer
volume including 10 μCi of [γ-33P] ATP (PerkinElmer Life Sciences,
Waltham, MA) and 0.1 μg of human recombinant active Akt1 (ΔPH,
S473D), Akt2 (δPH, S474D), Akt3 (117-end, S472D; Upstate Bio-
technology) or 5 ng of human recombinant PKC theta (Invitrogen)
for 30 minutes at 30°C. Beads were washed in kinase buffer, reducing
Laemmli buffer was added, and samples were resolved by SDS-PAGE.
The gel was fixed and stained by Coomassie Blue followed by exposure
to a PhosphoImager plate and detection with Typhoon Imager 9400
(both from GE Healthcare). For in vitro kinase assays of the full-length
protein, COS-7 cells were transfected with merlin constructs, and ex-
pressed proteins were immunoprecipitated with the C-terminal merlin
KF10 mAb. Immunoprecipitated proteins were phosphorylated in vitro
by Akt1 as described previously.
Mass Spectrometry Analysis
Merlin was immunoprecipitated from serum-starved transfected
COS-7 cells that were either EGF stimulated as described previously
or cotransfected with Akt myr. For identification, the immunoprecipi-
tated proteins were separated by SDS-PAGE and visualized with silver
staining [27], after which the protein bands were cut out from the
gel, in-gel digested with trypsin into peptides, and analyzed by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) using an
Ultimate 3000 nano-LC (Dionex, Sunnyvale, CA) and a QSTAR
Elite hybrid quadrupole TOF-MS (Applied Biosystems/MDS Sciex,
Foster City, CA) with nano–electrospray ionization as previously de-
scribed [28–30].
The LC-MS/MS data were searched with in-house Mascot ver-
sion 2.2 through ProteinPilot 2.0.1 interface against a self-made
database containing merlin sequence (SwissProt entry P35240). In
addition, searches were done against SwissProt database (version
57.10; 512,205 sequences). The search criteria for Mascot searches
were the following: trypsin digestion with three missed cleavages
allowed, carbamidomethyl (C) as fixed modification and oxidation
(M), phospho (ST), phospho (Y) as variable modifications. For the
LC-MS/MS spectra, the maximum precursor ion mass tolerance was
50 ppm, and MS/MS fragment ion mass tolerance of 0.2 Da and
peptide charge state of +1, +2, or +3 were used.
Affinity Pull-down
Transfected COS-7 cells were lysed in cold binding buffer (140 mM
NaCl, 1 mM Tris, pH 7.5) containing 0.5% Triton X-100 and com-
plete protease inhibitors, and the homogenates were cleared by centri-
fugation at 4°C for 20 minutes at 13,000g. G-Sepharose beads carrying
∼4 μg of bacterially produced GST fusion proteins were washed in
binding buffer and incubated with the lysates overnight at 4°C under
rotation. Samples were washed with binding buffer, and the bound
proteins were separated by SDS-PAGE, blotted, and detected with
the appropriate antibody. The blot was further stripped and reprobed
with GST Ab to verify equal amounts of proteins on the beads.
Quantifications
ImageQuant TL2003 software (GE Healthcare) was used to analyze
band intensities from immunoblots. Merlin intensities were normalized
to α-tubulin to obtain the merlin-tubulin ratio or the p-S518 amount
to total merlin to obtain the p-S518–merlin ratio. For quantification of
in vitro phosphorylation, the phospho-signal from the autoradiograph
read by Typhoon Imager 9400 was analyzed by ImageQuant TL2003
and normalized to the Coomassie Blue staining, and the background
radioactivity (untransfected cells) was subtracted from merlin samples.
All quantifications were done from at least three independent ex-
periments, and Student’s t test was used for calculation of P values.
In figures, mean ± SD is given.
Results
Merlin Is Phosphorylated on Serine 10 by All Akt Isoforms
To study the putative link between merlin and Akt, we first per-
formed an in vitro Akt phosphorylation assay with recombinant merlin
fragments. Full-length merlin (residues 1-595) is easily degraded when
produced as a GST fusion in bacteria; therefore, merlin 1-547 and
merlin 492-595 were used to cover the entire molecule. The Akt sub-
strate region in merlin was mapped to the very N-terminus of the pro-
tein, as merlin 1-100 was phosphorylated by Akt1 in vitro (Figure 1A).
Akt did not phosphorylate merlin C-terminus (492-595) in contrast to
the previously characterized merlin phosphorylating kinases, PAK and
PKA. Substitution of serine 10, previously identified as a substrate for
PKA [12], abrogated the phosphorylation in all merlin constructs,
showing that S10 is required for Akt phosphorylation. To test whether
merlin serves as a substrate for all AGC kinases, a subfamily of protein
kinases to which both PKA and Akt belong, a protein kinase C (PKC)
phosphorylation assay was performed. PKC phosphorylates merlin
N-terminus in vitro, but the S10A mutation does not affect the phos-
phorylation (Figure 1B). Therefore, it is unlikely that the diminished
phosphorylation of S10A constructs by Akt would result from general
misfolding of the merlin proteins.
Merlin threonine 230 and serine 315 were recently described as Akt
phosphorylation sites [24]. To test phosphorylation of these residues
and to confirm S10 phosphorylation in full-length merlin, the Akt
in vitro kinase assay was performed with full-length merlin with or
without alanine substitutions (S10A, T230A, S315A) in different
combinations, immunoprecipitated from transfected COS-7 cells.
Alanine substitution of threonine 230 and serine 315 had no effect
on Akt phosphorylation, whereas S10A mutation resulted in loss of
phosphorylation in all constructs (Figure 1C ). These results indicate
that S10 is the sole target of Akt. To further confirm S10 phosphory-
lation, a phospho-specific antibody against phospho-S10 was raised.
The phospho-S10 Ab recognized GST-merlin 1-547 phosphorylated
by Akt, whereas S10A-containing constructs or unphosphorylated
merlin was not detected by the antibody (Figure 1D).
To rule out that the conflicting results between our study and those
published before were due to the use of different Akt isoforms, we
studied the effect of the three kinases on merlin phosphorylation.
The merlin 1-547 constructs were similarly phosphorylated by all
isoforms, and mutation of S10 was sufficient to abolish the phosphory-
lation (Figure 1E). However, phosphorylation was not affected by the
T230A and S315A mutations.
Finally, to study whether merlin S10 is an Akt substrate in vivo, merlin
was expressed in COS-7 cells, which were either epidermal growth fac-
tor (EGF) stimulated to activate Akt or coexpressed with myristoylated
Akt (Akt myr), a constitutively activated and membrane-targeted form
of Akt. Merlin was immunoprecipitated, resolved in SDS-PAGE, and
silver stained. Bands were subjected to proteolytic cleavage and analyzed
by MS. Analysis of the EGF-stimulated merlin MS spectra revealed
several phosphorylated peptides, among them the peptide correspond-
ing to merlin residues 9-16 containing phospho-serine 10 (data not
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shown). Proteins from merlin and Akt myr–cotransfected cells were also
studied, but interestingly, no phosphorylated peptides were detected in
this sample.
Merlin and Akt Colocalize and Interact Both In Vitro
and In Vivo
Although stable complex formation between the kinase and its
substrate is not generally required for phosphorylation, many Akt
substrates have been shown to form detectable complexes with the
kinase. The interaction may promote substrate phosphorylation and/
or anchor Akt in different cellular compartments allowing localized sig-
naling networks [31]. Because Akt-mediated phosphorylation of merlin
was confirmed, colocalization between these proteins was studied.
Merlin WT and S10A constructs were cotransfected with Akt1 into
COS-7 cells, and the cells were treated with EGF or the PI3K inhibitor
LY294002 to either activate or inactivate Akt. Both WT and S10A
merlin colocalized with active Akt at the cell membrane in EGF-treated
cells (Figure 2A, upper and middle panels). Akt1 showed nuclear stain-
ing in PI3K inhibitor–treated cells, whereas merlin was still present at
the cell membrane (Figure 2A, lower panels). The same localization
Figure 1. All Akt isoforms phosphorylate merlin at serine 10. (A) Recombinant GST-merlin fragments were Akt-phosphorylated in vitro,
separated on SDS-PAGE and exposed (upper panel). The Coomassie Blue staining shows loading of the proteins (lower panel) and
arrowheads mark the merlin GST constructs. Merlin 1-100, 1-314, and 1-547 are phosphorylated by Akt1, and the S10A substitution
abolishes the phosphorylation. (B) GST-merlin fragments were phosphorylated in vitro by PKC, exposed (upper panel), and stained with
Coomassie Blue (lower panel). Merlin 1-314 is phosphorylated by PKC, but S10A mutation does not affect the phosphorylation. (C) Full-
length wild-type (WT) merlin and merlin mutants were expressed in COS-7 cells, immunoprecipitated, and subjected to an in vitro Akt
kinase assay. Immunoprecipitation from untransfected cells (−) was used as a negative control. WT merlin is phosphorylated by Akt,
whereas phosphorylation is decreased in both S10A-containing constructs (upper panel). Substitution of T230 or S315 does not affect
phosphorylation. The Coomassie Blue staining shows equal loading (middle panel) and the lower panel shows immunoprecipitated merlin.
(D) In vitro kinase assay with merlin GST proteins incubated with (+) or without (−) Akt1 was detected with phospho-S10 Ab (left panel) and
GST Ab (right panel). The phospho-S10 antibody detects Akt1 incubated merlin 1-547 but not S10A or untreated 1-547. (E) GST-merlin
fusion proteins were phosphorylated with Akt1, Akt2, and Akt3 kinases. Proteins were resolved on SDS-PAGE, stained with Coomassie
Blue (lower panels), and exposed (upper panels). Merlin 1-547 is phosphorylated by all Akt isoforms, and the S10A mutation abolishes the
phosphorylation. T230A and S315A substitutions have no effect on phosphorylation.
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pattern was detected in Nf2−/− mouse embryonic fibroblasts (data
not shown).
To further investigate the interaction of merlin and Akt and to map
the binding region, an affinity pull-down assay was performed. Mer-
lin GST proteins were incubated with lysates from Akt1-transfected
COS-7 cells, and the amount of bound Akt1 was analyzed. Figure 2B
demonstrates that the FERM domain containing constructs 1-314
and 1-547 bind Akt1 in vitro, whereas the binding affinity to α-helical
314-477 and C-terminal 492-595 constructs was very weak. Because
merlin 1-547 binding was stronger than the interaction observed with
1-314, it is possible that merlin 1-547 contains not only the N-terminal
but also another more C-terminal binding site. Merlin S10 seems not
to be critical for binding as S10A substitution bound Akt with similar
affinity as WT.
To verify the binding, a coimmunoprecipitation assay with full-
length merlin WT or S10A and Akt was performed from cotransfected
COS-7 cell lysates. Our data show that merlin and Akt1 bind in vivo
and confirm that the association is independent of the S10 phosphory-
lation (Figure 2C ). Treatment of the cells with EGF did not change
the binding affinity of merlin and Akt (data not shown).
Akt-Phosphorylated Merlin Is Degraded through
a Proteasome-Dependent Pathway
In an attempt to further analyze serine 10 phosphorylation in vivo,
merlin was immunoprecipitated from COS-7 lysates cotransfected with
constitutively active Akt myr. Interestingly, significantly less merlin
was detected in immunoprecipitates from cells in which Akt myr was
overexpressed (data not shown). The low levels of merlin together with
the MS analysis data, which showed that no phospho-peptides of
merlin could be detected in Akt myr transfectants, suggested that
merlin is degraded in response to Akt phosphorylation. To test this
hypothesis, merlin WT and S10A were transfected into COS-7 cells
together with either Akt myr or myristoylated kinase dead Akt (Akt
KD). Akt KD–transfected cells were also treated with PI3K inhibi-
tor to reduce endogenous Akt activity, and the Akt myr–transfected
cells were incubated with the phosphatase inhibitor Calyculin A to
increase the level of phosphorylated merlin. The phospho-Akt and
phospho-GSK3 immunoblots confirm that Akt is activated in Akt
myr–transfected cells (Figure 3A). Results show that the amount of
WT merlin was significantly decreased and was, on an average, reduced
by 65% in Akt myr–expressing cells compared with cells expressing
Figure 2. Merlin and Akt association in vivo and in vitro. (A) COS-7 cells were cotransfected with Akt1 and merlin WT or S10A and
treated with EGF or LY294002 (PI3K inh.). Cells were stained for merlin (green) and Akt (red, top, and bottom) or phospho-Ser 473 Akt
(p-Akt, red, middle). Merlin colocalizes with activated Akt at the cell membrane (arrowheads), and mutation of serine 10 does not affect
merlin-Akt colocalization (right panel). (B) Glutathione bead–conjugated GST-merlin constructs were incubated with lysates from Akt1-
transfected COS-7 cells and bound proteins were detected with Akt Ab (upper panel) and merlin with GST Ab (lower panel). Merlin
N-terminus–containing fragments (1-100, 1-314, 1-547) bind Akt1 in vitro. The Akt binding affinity is not weakened by the S10A mutation.
(C) Cotransfected merlin and Akt1 were coimmunoprecipitated from COS-7 cell lysates. Proteins were detected with merlin KF10 and
pan-Akt antibodies and untransfected cells (−) were used as control. Both WT and S10A merlin interact with Akt1 in vivo.
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Akt KD (Figure 3A). Incubation with Calyculin A further increased
the degradation of WT merlin. As expected, S10A merlin was more
resistant to Akt myr–induced degradation than WT. The mild de-
crease detected in the amount of S10A merlin may be a result of the
alanine substitution at S10, which does not fully mimic the un-
phosphorylated residue and is therefore not sufficient to completely
inhibit degradation. Both the detergent-insoluble and -soluble WT
merlin were degraded because of Akt myr overexpression (Figure 3B).
To determine the pathway that mediates the degradation of merlin,
cells coexpressing merlin and Akt myr were treated with the pro-
teasomal inhibitor MG132 or with Bafilomycin A1 to inhibit lysosomal
function. The amount of merlin was quantified and compared with the
level in untreated Akt KD–expressing cells. Treatment of cells express-
ing Akt myr and merlin with MG132 increased the amount of merlin
from 20% in untreated cells to an average of 49%, whereas Bafilo-
mycin A1 had no significant effect on the merlin level (Figure 3C ).
These results indicate that Akt-phosphorylated merlin is degraded
through the proteasomal pathway. Proteins targeted for proteasomal
degradation are tagged with ubiquitins. To analyze the ubiquitination
of merlin, immunoprecipitated WT and S10A merlin from MG132
treated COS-7 cells were immunoblotted for ubiquitin (Figure 3D).
Both WT and S10A merlin are monoubiquitinated independently of
Akt, but soluble polyubiquitinated merlin was not detected.
C-terminal Phosphorylation of Merlin Increases
Serine 10 Phosphorylation
Because both Akt and PKA phosphorylate merlin S10, we next
looked at the interplay between PKA and Akt and their effect on mer-
lin degradation. Merlin WT was cotransfected into COS-7 cells with
either Akt KD or Akt myr. The Akt myr–transfected cells were treated
with the PKA inhibitor H89 to inhibit endogenous PKA activity or
with forskolin and IBMX to activate PKA. The results show that Akt-
induced merlin degradation is not PKA dependent because merlin is
also degraded in H89-treated cells (Figure 4A). However, coactivation
of Akt and PKA has an additive effect on merlin degradation.
Figure 3. Constitutively active Akt degrades WT merlin through the proteasomal pathway. (A) COS-7 cells cotransfected with WT or S10A
merlin and inactive (Akt KD) or constitutively active (Akt myr) Akt were untreated or treated with the phosphatase inhibitor Calyculin A
(Calyc.) or PI3K inhibitor LY294002 (PI3K inh.). Lysates were run in SDS-PAGE and detected for merlin (A-19 Ab), phospho-Ser 473 Akt
(p-Akt), Akt, phospho-GSK3 (p-GSK3), GSK3, and α-tubulin as a loading control. The merlin/tubulin ratio is shown in the lower chart
and 100% represents the merlin level in Akt KD–expressing cells. The amount of WT merlin in cells expressing Akt myr is significantly
decreased compared with cells expressing Akt KD, whereas S10A merlin is less sensitive to Akt myr coexpression. (B) Lysates from
COS-7 cells cotransfected with merlin and Akt KD or Akt myr were separated into insoluble (I) and soluble (S) fractions and run in SDS-
PAGE (upper panel). The merlin-tubulin ratio was quantified, and the amount of merlin in fractions is shown in arbitrary units (lower chart).
Both the detergent-insoluble and -soluble WT merlin is degraded in Akt myr–transfected cells. (C) COS-7 cells were cotransfected with
merlin WT and Akt KD or Akt myr. The WT + Akt myr–expressing cells were untreated or treated with MG132 or Bafilomycin A1 (Baf.),
and lysates were detected with merlin A-19 Ab, α-tubulin Ab, and ubiquitin Ab (left panels). The merlin amount was quantified, and the
level in WT + Akt KD–transfected cells was regarded as 100% (right chart). The proteasome inhibitor MG132 increases the amount of
merlin in Akt myr–expressing cells. (D) WT and S10Amerlin was immunoprecipitated from untransfected or Akt-transfected EGF-stimulated
and MG132-treated COS-7 cells. Samples were detected for ubiquitin (upper panel) and merlin (middle panel). The expression of Akt was
confirmed from the lysates with Akt antibody (lower panel). Merlin WT and S10A are equally ubiquitinated. **P < .01. *P < .05.
648 Akt Phosphorylation of Merlin Serine 10 Laulajainen et al. Neoplasia Vol. 13, No. 7, 2011
Phosphorylation of S518 is known to regulate the tumor-suppressive
activity of merlin. To study the interplay between the N- and C-terminal
phosphorylation sites, an Akt kinase assay was conducted. Merlin
full-length constructs with serine-to-alanine substitutions produced
in COS-7 cells were immunoprecipitated, and bound proteins were
phosphorylated in vitro by Akt. Because the merlin constructs were pro-
duced in COS-7 cells, the proper conformation of the proteins should
be retained. The chart in Figure 4B shows the quantification of auto-
radiographs when the signal in merlin WT was regarded as 100%. In
merlin S518D, mimicking the phosphorylated form, Akt phosphoryla-
tion of S10 was significantly increased compared with WT. Conse-
quently, S10 phosphorylation of S518A merlin was lower than WT.
Mutation of T230 and S315 were shown to influence merlin func-
tion [24,32]. Although we could not detect Akt phosphorylation of
these residues, their possible effect on merlin phosphorylation was
analyzed. COS-7 cells were transfected with the mutants and lysates
were detected with the phospho-S518 merlin Ab. Interestingly, alanine
substitutions of T230 and S315 abrogated C-terminal S518 phos-
phorylation of merlin (Figure 4C).
Serine 10 Modifications Affect Binding of Merlin to DCAF1
The attachment of ubiquitins on proteins marked for proteasomal
degradation is catalyzed by ubiquitin ligases. An interaction with VprBP/
DCAF1 (DDB1- and Cul4-associated factor 1) has been shown to
target merlin to the Roc1-Cul4A-DDB1 E3 ligase complex leading
to merlin’s polyubiquitination and proteasome-dependent degrada-
tion [33]. As our assays indicated that merlin is degraded through the
proteasome in response to N-terminal phosphorylation, we studied
whether phosphorylation of serine 10 targets merlin to the E3 ligase
complex, directing it for degradation.
Merlin interacts with DCAF1 through its N-terminus [25,33]. To
analyze whether S10 of merlin is regulating the interaction, a pull-down
assay with recombinant merlin fragments and transfected DCAF1 was
conducted. Figure 5A shows that a binding site in merlin exists be-
tween residues 100 and 314. Mutation of S10 or S518 did not affect
the binding affinity of the fragments, showing that these residues are
not directly required for binding in vitro.
Although S10 is not included in the binding region of DCAF1, co-
immunoprecipitation experiments were conducted with full-length pro-
teins to study whether modifications of S10 affect the merlin-DCAF1
association in vivo.Merlin S518DassociatedwithDCAF1 stronger than
WT did, but interestingly, mutation of S10 significantly decreased the
binding of S518D to DCAF1 (Figure 5B). Although S10 is not directly
included in the binding region, modifications of this residue can lead
to changes, which disrupt the interaction with DCAF1 in vivo.
Discussion
The kinase experiments and MS analysis of merlin in this report
confirm S10 as a site for Akt-mediated phosphorylation. Within the
first 17 amino acids of merlin, several possible phosphorylated residues
Figure 4. Effect of mutants on merlin phosphorylation. (A) COS-7 cells were cotransfected with merlin WT and Akt KD or Akt myr, and
WT + Akt myr–expressing cells were untreated or treated with H89 to inhibit PKA activity or with forskolin and IBMX (F + I) to increase
PKA activity. Lysates were detected with merlin A-19 Ab, α-tubulin Ab, phospho-Ser473 Akt Ab (p-Akt), and Akt Ab (upper panels). The mer-
lin amount was quantified, and the level in WT + Akt KD–transfected cells was regarded as 100% (lower chart). Coactivation of Akt and
PKA increases merlin degradation. (B) Merlin constructs were expressed in COS-7 cells, immunoprecipitated and phosphorylated in vitro
using Akt1. The ratio of phospho-signal from autoradiograph normalized to protein amount when WT is 100% is shown in the lower chart.
Untransfected cells (−) were used as a negative control. Serine 10 phosphorylation is increased in S518D and decreased in S518A com-
pared with merlin WT. (C) Cell lysates from COS-7 cells transfected with merlin constructs were immunoblotted with merlin phospho-serine
518 antibody (p-S518 Ab) and merlin antibody A-19. The graph illustrates the ratio between merlin S518 phosphorylated over total merlin
when WT is regarded as 100%. Serine 518 phosphorylation is significantly decreased in T230A + S315A merlin. **P < .01. *P < .05.
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including serine 10 have been predicted based onMS analysis [34], and
by using metabolic labeling, we have previously identified S10 as a PKA
phosphorylation site [12]. Although S10 serves as a substrate residue
for both PKA and Akt, it is not phosphorylated by all AGC kinase
family members because S10A mutations do not affect PKC-mediated
phosphorylation of merlin. Akt is known to phosphorylate proteins
containing the consensus sequence R-X-R-X-X-S/T-F/L, where the
arginines at positions −3 and −5 seem to be the most critical [35]. How-
ever, S10 is located in a sequence with an arginine at position −2. Also,
unconventional Akt phosphorylation sequences have been reported,
but they all contain an arginine upstream of the phosphorylated residue
[36,37]. The ability of Akt to phosphorylate proteins with arginine in
position −2 has not been previously reported, thus merlin represents a
novel Akt substrate sequence.
The low levels of merlin in response to coexpression of constitutively
active Akt lead us to hypothesize that merlin is degraded in response
to Akt phosphorylation, and this was confirmed by mutating S10,
which significantly reduced the Akt-induced degradation. We could
not detect similar degradation of merlin with the membrane-targeted
kinase-dead Akt or in response to EGF treatment as observed when
using constitutively active Akt. This suggests that the phosphorylation
status of merlin is tightly regulated and that only the active membrane-
targeted Akt myr is able to induce the specific and efficient phos-
phorylation of merlin. Inhibition of the proteasome increased the
amount of merlin protein and attenuated Akt-induced degradation,
and therefore, we conclude that merlin is degraded in response to
S10 phosphorylation through the proteasomal pathway. PKA, which
also phosphorylates merlin S10, is not required for Akt-mediated
degradation of merlin, but coactivation of both Akt and PKA has
an additive effect on merlin degradation. In accordance, Nf2 is post-
transcriptionally lost in TEC3KO mice with increased PKA activity,
suggesting that PKA can also regulate the stability of merlin [38].
Akt-mediated phosphorylation of merlin leading to its degradation
has previously been described, but the effect was claimed to be medi-
ated through threonine 230 and serine 315 [24]. We could not find
an explanation for this discrepancy because all Akt isoforms phos-
phorylated merlin exclusively on S10; however, it may be explained
by different cell lines used and distinct experimental setups. Our re-
sults also show that the association of merlin and Akt is direct through
at least a strong N-terminal Akt binding site, but phosphorylation of
S10 is not required for the merlin-Akt interaction.
To investigate the interplay between the identified functionally
important residues in merlin, the phosphorylation of mutated pro-
teins was studied. The assays show that C-terminal S518 phosphoryla-
tion of merlin increases N-terminal S10 phosphorylation, suggesting
that S518 phosphorylation is the primary event in the functional
regulation of merlin. S518 phosphorylation might enhance N-terminal
phosphorylation by affecting the intramolecular structure of merlin,
as C-terminal phosphorylation is believed to promote a conforma-
tional change by disrupting the N- to C-terminal association. How-
ever, because S10 is located in the very N-terminal region outside
the FERM domain [39,40], it is not determined whether the residue
is masked by the C-terminus in the closed conformation. Interestingly,
S518 phosphorylation of merlin was significantly decreased in the
T230A + S315A construct. Mutation of T230 and S315 has been
shown to perturb the intramolecular self-association of merlin [24].
Figure 5. Merlin-DCAF1 interaction in vitro and in vivo. (A) Glutathione bead–conjugated GST-merlin constructs were incubated with
lysates from DCAF1 transfected COS-7 cells, and bound proteins were detected with antibody against DCAF1 (upper panel) and merlin with
GST Ab (lower panel). Merlin 1-314 binds DCAF1, whereas 1-100, 314-477, and 492-595 merlin show no binding. Mutation of S10 does
not affect the DCAF1 binding affinity of merlin fragments. (B) DCAF1 was immunoprecipitated from merlin and DCAF1-cotransfected
COS-7 cell lysates, and merlin was detected with KF10 Ab (upper panel). Equal amounts of proteins were expressed as shown in lysates
(lower panels), and untransfected cells (−) were used as control. S518D merlin interacts strongly, whereas S10A + S518D merlin shows
reduced binding affinity to DCAF1.
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Thus, disruption of the merlin conformation may affect S518, leading
to the decrease in phosphorylation observed. Some of the effects re-
ported for T230 + S315 mutants, such as their impact on apoptosis
and cell motility [24,32], might therefore be secondary events resulting
from abrogated C-terminal phosphorylation without involving direct
Akt-mediated phosphorylation.
Merlin has recently been described to suppress tumorigenesis by
translocating to the nucleus to inhibit the E3 ligase CRL4DCAF1 [25].
The authors showed that, in the nucleus, merlin functions as a neg-
ative regulator of the ligase by inhibiting its ubiquitinating activity.
Our data, however, show that modification of S10 affects the merlin-
DCAF1 interaction in the soluble fraction of cells, possibly through
a conformational transformation of merlin N-terminus, which could
target merlin for degradation. This is consistent with the recent data
that DCAF1 mediates the degradation of merlin [33]. It remains to
be studied whether merlin is a downstream effector of Akt at the mem-
brane but an upstream regulator of DCAF1 in the nucleus.
On the basis of our results and previous studies, we propose a model
for a nongenetic mechanism of merlin inactivation (Figure 6). In
growth-inhibitory conditions, merlin exists in a closed conformation
through N- to C-terminal association, unphosphorylated on serine 518.
Growth factor signaling results in phosphorylation of merlin S518 either
by PKA or PAK, which renders merlin in an open conformation. This
form is subsequently phosphorylated on S10 by either Akt or PKA.
Phosphorylation at the N-terminus targets merlin for proteasome-
mediated degradation by its DCAF1 interaction or with additional
unknown mechanisms. Consequently, merlin’s growth-inhibitory func-
tion is efficiently inhibited. In accordance with the detected degrada-
tion of merlin, coexpression of constitutively active Akt with merlin
has been shown to diminish merlin’s proapoptotic action [32].
The phosphorylation status of merlin is strictly controlled and com-
partmentalized because only membrane-targeted constitutively active
Akt induces degradation of merlin. The S10-dependent degradation
of merlin may occur as a consequence of Akt pathway hyperactivation,
a common feature in malignant neoplasias. Although difficult to un-
equivocally confirm, we postulate that temporal transient phosphoryla-
tion of S10 regulates the cytoskeletal functions of merlin [12], whereas
constitutive phosphorylation in malignant cells leads to merlin deg-
radation. Further studied are needed to determine whether Akt-
mediated S10 phosphorylation plays a role in the normal functional
regulation of merlin or whether it is just a consequence of Akt over-
activation in neoplasia.
Multiple tumor types harbor mutations in components of the PI3K/
Akt pathway leading to increased Akt signaling [13], and mutations
and loss of merlin expression have been reported in several tumor types
in addition to those associated with NF2 [41,42]. For example, in
malignant gliomas, merlin expression is reduced [43], and the PI3K
signaling pathway is activated [44]. Recently, a compound targeting
the Akt pathway was investigated as a chemotherapeutic in preclinical
studies for vestibular schwannomas, tumors associated with NF2
[45]. It remains to be seen whether inactivation of this pathway will
reduce tumor cell growth and have therapeutic potential for patients
with NF2.
In conclusion, our results suggest that degradation of the tumor
suppressor merlin is enhanced as a consequence of overactivation of
the Akt pathway and hence merlin phosphorylation. Activation of
the PI3K/Akt pathway could therefore represent a novel way to in-
activate merlin in tumors that lack NF2 mutations.
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